David A. Siegel Tarsus Pharmaceuticals, Inc. Transaction History
Two Sigma Advisers, LP
- $43.8 Billion
- Q2 2024
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Tarsus Pharmaceuticals, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 307,600 shares of TARS stock, worth $10 Million. This represents 0.02% of its overall portfolio holdings.
Number of Shares
307,600
Previous 73,900
316.24%
Holding current value
$10 Million
Previous $2.69 Million
211.24%
% of portfolio
0.02%
Previous 0.01%
Shares
8 transactions
Others Institutions Holding TARS
# of Institutions
155Shares Held
40.4MCall Options Held
37.9KPut Options Held
808K-
Rtw Investments, LP New York, NY3.41MShares$111 Million1.55% of portfolio
-
Black Rock Inc. New York, NY3.27MShares$106 Million0.0% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY2.44MShares$79.2 Million2.68% of portfolio
-
Tang Capital Management LLC San Diego, CA2.25MShares$73.3 Million7.48% of portfolio
-
Cowen And Company, LLC2.2MShares$71.4 Million1.53% of portfolio
About Tarsus Pharmaceuticals, Inc.
- Ticker TARS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 26,658,500
- Market Cap $867M
- Description
- Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as...